A recent study has provided the most detailed look yet at the genetic makeup of colorectal cancer, one of the leading causes of death worldwide.
Colorectal cancer, like other cancers, develops when cells in the body undergo genetic changes that cause them to grow uncontrollably.
Despite its prevalence, we still don’t fully understand the genetic changes that drive this disease.
This new research, led by teams from prominent U.K. universities such as The Institute of Cancer Research in London, the University of Oxford, and the University of Manchester, offers a more complete picture of the genetic landscape of colorectal cancer.
The study was published in the journal Nature and is considered a significant advancement in understanding how this cancer develops and responds to treatments.
The research made use of data from 2,023 bowel cancer samples, collected as part of the 100,000 Genomes Project—a large initiative led by Genomics England and NHS England.
By analyzing these samples, the researchers were able to identify new genetic faults that lead to the development of colorectal cancer.
They also discovered new sub-groups of the disease, which are categories of cancer with specific genetic traits that influence how the cancer behaves and responds to treatments. These findings offer valuable insights into the disease’s progression and point to potential new treatment strategies.
In their analysis, the researchers identified over 250 genes that play crucial roles in colorectal cancer. Most of these genes had not been previously associated with this or any other type of cancer, expanding our understanding of the genetic factors involved in the disease.
The study also revealed four common sub-groups of colorectal cancer based on genetic features, as well as several rare sub-groups. These groups have different patient outcomes and may require different treatment approaches.
One of the key discoveries was the identification of various genetic changes that occur in different regions of the colorectum, highlighting the differences in how colorectal cancer develops among individuals.
For instance, the study found a particular process that is more active in the cancers of younger patients. While the exact cause of this process remains unknown, it could be related to factors such as diet and smoking.
The researchers also noted that many of the mutations they identified could potentially be targeted with existing treatments that are currently used for other types of cancer.
Professor Ian Tomlinson from the University of Oxford, one of the lead researchers, emphasized the importance of these findings.
He explained that by gaining a better understanding of the genetic changes involved in colorectal cancer, we can improve our ability to predict patient outcomes and develop new treatment strategies. This could include the use of anti-cancer drugs that are not currently used for colorectal cancer.
The results of this study provide a valuable resource for the scientific community and lay the groundwork for future research. The data is available to other researchers who are encouraged to build on these findings by conducting more focused studies on the colorectal cancer genome.
Professor Richard Houlston from The Institute of Cancer Research in London, another lead researcher, highlighted how this study offers crucial insights into the biology of colorectal cancer, revealing clues about how the disease develops, grows, and responds to treatment.
He expressed hope that future studies will use these findings to create more personalized treatments for patients based on their genetic makeup.
Professor David Wedge from the University of Manchester, who also co-led the study, pointed out that this research is one of the first large-scale studies to emerge from the 100,000 Genomes Project.
He expects that this study will be followed by many more investigations into various types of cancer, using the extensive data provided by Genomics England.
In addition to these findings, Dr. Henry Wood from the University of Leeds noted that this study is the first to provide in-depth whole-genome sequencing of the microbiome—the community of bacteria and viruses in the gut—in a large number of colorectal cancer cases.
This new data opens the door to exploring the role of the microbiome in cancer development and whether altering it could improve patient outcomes.
Overall, this study represents a major step forward in our understanding of colorectal cancer, offering new possibilities for treatment and better outcomes for patients.
If you care about cancer, please read studies about a new method to treat cancer effectively, and this low-dose, four-drug combo may block cancer spread.
For more information about cancer prevention, please see recent studies about nutrient in fish that can be a poison for cancer, and results showing this daily vitamin is critical to cancer prevention.
The research findings can be found in Science Advances.
Copyright © 2024 Knowridge Science Report. All rights reserved.
